The Results of ADVANCE‐CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Documenti analoghi

• Long‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial
  di: Robert D. M. Hadden, et al.
  Pubblicazione: (2024)
• A Comparative Real‐World Study Evaluating the Safety of Immune Globulin Infusion (Human) 10% Solution and Other Intravenous Immunoglobulin Therapies for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  di: J. Bradley Layton, et al.
  Pubblicazione: (2025)
• Daratumumab Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy ( CIDP ): A Case Report
  di: Xueyu Zhang, et al.
  Pubblicazione: (2025)
• Chronic Inflammatory Demyelinating Polyradiculoneuropathy ( CIDP ) Developing During Tacrolimus Treatment: A Case Series
  di: Matthew C. Evans, et al.
  Pubblicazione: (2025)
• Validation of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Coding in US Claims Data
  di: Joshua U. Okonkwo, et al.
  Pubblicazione: (2025)